ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
https://www.investegate.co.uk/glaxosmit ... 00043780R/
Thanks to eyeball08,Wondergirly,bofh,johnstevens77,Bhoddhisatva, for Donating to support the site
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
monabri wrote:To counter ULVRs drop today, GSK is currently at 1576p ... increased from 1242p on Feb 6th 2018.
(even BT has a smile on it's face!)
idpickering wrote:Positive headline results for ViiV GEMINI studiesViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
https://www.investegate.co.uk/glaxosmit ... 00043780R/
Return to “HYP Practical (See Group Guidelines)”
Users browsing this forum: Cedarling and 24 guests